- Home
- NAVI vs SNDX Comparison
NAVI vs SNDX Comparison
Compare NAVI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- SNDX
- Stock Information
- Founded
- NAVI 1973
- SNDX 2005
- Country
- NAVI United States
- SNDX United States
- Employees
- NAVI N/A
- SNDX N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- SNDX Health Care
- Exchange
- NAVI Nasdaq
- SNDX Nasdaq
- Market Cap
- NAVI 1.8B
- SNDX 1.6B
- IPO Year
- NAVI N/A
- SNDX 2016
- Fundamental
- Price
- NAVI $15.14
- SNDX $15.83
- Analyst Decision
- NAVI Sell
- SNDX Strong Buy
- Analyst Count
- NAVI 8
- SNDX 11
- Target Price
- NAVI $14.75
- SNDX $36.00
- AVG Volume (30 Days)
- NAVI 740.6K
- SNDX 1.7M
- Earning Date
- NAVI 10-30-2024
- SNDX 11-05-2024
- Dividend Yield
- NAVI 4.23%
- SNDX N/A
- EPS Growth
- NAVI N/A
- SNDX N/A
- EPS
- NAVI 0.70
- SNDX N/A
- Revenue
- NAVI $1,036,000,000.00
- SNDX $16,000,000.00
- Revenue This Year
- NAVI N/A
- SNDX N/A
- Revenue Next Year
- NAVI $1.01
- SNDX $219.92
- P/E Ratio
- NAVI $21.72
- SNDX N/A
- Revenue Growth
- NAVI N/A
- SNDX N/A
- 52 Week Low
- NAVI $13.71
- SNDX $14.81
- 52 Week High
- NAVI $19.68
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- NAVI 49.23
- SNDX 32.96
- Support Level
- NAVI $15.18
- SNDX $16.03
- Resistance Level
- NAVI $15.68
- SNDX $17.87
- Average True Range (ATR)
- NAVI 0.51
- SNDX 0.93
- MACD
- NAVI 0.06
- SNDX -0.45
- Stochastic Oscillator
- NAVI 58.61
- SNDX 1.26
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.